Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $169 from $175 and keeps a Neutral rating on the shares. The firm said discrete customer decisions to defer ramps on new product intros, combined with capital goods demand softnes at year-end 2024 all contributing to revisions.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.